10-Q: Encision Inc. Reports Q3 2025 Results: Net Loss Decreases Despite Product Revenue Dip

Encision Inc. reports a decreased net loss for Q3 2025, driven by improved gross margins, despite a slight decrease in product revenue.

Summary

• Encision Inc. reported its financial results for the third quarter of fiscal year 2025, ending December 31, 2024.
• The company experienced a decrease in net product revenue for the quarter, falling to $1,457,402 from $1,561,103 in the same period last year, a 7% decrease.
• Net service revenue increased significantly to $128,179, compared to $20,461 in the prior year, due to services performed under a Master Services Agreement.
• Gross profit increased by 17% to $850,290, compared to $727,239 in the same quarter of the previous year.
• The gross margin on product net revenue improved to 54% from 46% due to price increases and higher operating efficiencies.
• Operating expenses decreased slightly, with sales and marketing expenses down 9% and research and development expenses down 8%.
• The net loss decreased to $24,668, compared to a net loss of $207,130 in the same quarter of the previous year.
• For the nine-month period, net product revenue decreased by 5% to $4,703,181, while net service revenue increased to $268,718.
• The company's accumulated deficit stood at $22,717,936 as of December 31, 2024.
• The company had $347,919 in cash and a line of credit for up to $718,473, restricted by eligible account receivables.
• The company is addressing a material weakness in internal controls related to revenue recognition and inventory reserves.
• Management believes that cash resources and the line of credit will be sufficient to meet cash requirements for the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While product revenue decreased, the company reduced its net loss and improved gross margins. The company is also addressing internal control weaknesses, which is a positive step. However, the accumulated deficit and reliance on debt financing are concerning.

Positives

• The net loss decreased significantly for both the quarter and the nine-month period.
• Gross profit increased due to improved gross margins and operating efficiencies.
• Net service revenue increased substantially, indicating growth in that segment.
• The company's cash position improved during the nine-month period.
• The company is actively addressing material weaknesses in internal controls.
• The company increased the pricing of products to mitigate higher material costs.

Negatives

• Net product revenue decreased for both the quarter and the nine-month period.
• The company has an accumulated deficit of $22,717,936.
• The company identified a material weakness in its internal control over financial reporting.
• The company's disclosure controls and procedures over financial reporting were not effective during the reporting period ending December 31, 2024.
• Working capital decreased by $130,924 from March 31, 2024.

Risks

• The company's future liquidity could be diminished due to operating losses, potentially requiring additional capital.
• The company's ability to increase sales and achieve profitable operations is uncertain.
• The company's success depends on surgeon preference for its instruments.
• The company is subject to regulation by the FDA, and compliance is essential.
• The company's net operating loss carryforwards may be limited by changes in ownership interests.
• The company's efforts to increase market share and grow product revenue depend on the efficiency of its sales representatives and the quality of its product offerings.
• The omission or delay of elective surgeries would negatively impact the extent and timing of revenue growth.

Future Outlook

The company aims to optimize sales execution, expand market awareness of AEM technology, and increase the number of hospital and surgery center accounts switching to AEM instruments. The company also intends to develop more disposable versions of its AEM products and explore overseas markets for international sales growth.

Management Comments

• Management is developing plans to ensure the Company has the working capital necessary to fund operations.
• Management concludes that it is probable that cash resources and line of credit will be sufficient to meet cash requirements for twelve months from the issuance of the unaudited condensed financial statements.

Industry Context

The company operates in the medical device industry, specifically focusing on minimally invasive surgery. The report mentions the Hospital-Acquired Condition Reduction Program, indicating a focus on patient safety and quality indicators within the healthcare sector. The company believes its AEM technology addresses a well-documented hazard in laparoscopic surgery, positioning it within the competitive landscape of electrosurgical devices.

Comparison to Industry Standards

• It's difficult to provide a precise comparison to industry standards without knowing Encision's specific market share and the performance of its direct competitors.
• Companies like Medtronic, Johnson & Johnson, and Stryker are major players in the broader medical device market, but they may not directly compete with Encision's niche AEM technology.
• A more relevant comparison would involve companies specializing in electrosurgical devices and those focused on patient safety solutions in minimally invasive surgery.
• Assessing Encision's gross margin of 53% against the industry average for medical device companies would provide insight into its operational efficiency.
• Benchmarking Encision's sales and marketing expenses as a percentage of net sales against similar-sized companies in the medical device sector would be valuable.

Related Party Transactions

• The Company engaged Finance Vision Service, Inc., a company owned by board member Robert Fries for consulting services.

Stakeholder Impact

• Shareholders may be concerned about the decrease in product revenue and the accumulated deficit.
• Employees may be affected by the company's efforts to optimize sales execution and manage operating costs.
• Customers (surgeons and hospitals) may benefit from the company's focus on patient safety and the development of new products.
• Suppliers may be impacted by the company's efforts to reduce the cost of product revenue.
• Creditors are exposed to the risk of the company's ability to repay its debts.

Next Steps

• The company plans to optimize sales execution, expand market awareness of AEM technology, and maximize the number of hospital and surgery center accounts switching to AEM instruments.
• The company intends to develop more disposable versions of its AEM products.
• The company is exploring overseas markets to assess opportunities for international sales growth.
• The company intends to explore opportunities to capitalize on its proven AEM technology via licensing arrangements and strategic alliances.

Key Dates